Genome-wide 5-Hydroxymethylcytosine Profiling Analysis Identifies MAP7D1 as A Novel Regulator of Lymph Node Metastasis in Breast Cancer

Although DNA 5-hydroxymethylcytosine (5hmC) is recognized as an important epigenetic mark in cancer, its precise role in lymph node metastasis remains elusive. In this study, we investigated how 5hmC associates with lymph node metastasis in breast cancer. Accompanying with high expression of TET1 and TET2 proteins, large numbers of genes in the metastasis-positive primary tumors exhibit higher 5hmC levels than those in the metastasis-negative primary tumors. In contrast, the TET protein expression and DNA 5hmC decrease significantly within the metastatic lesions in the lymph nodes compared to those in their matched primary tumors. Through genome-wide analysis of 8 sets of primary tumors, we identified 100 high-confidence metastasis-associated 5hmC signatures, and it is found that increased levels of DNA 5hmC and gene expression of MAP7D1 associate with high risk of lymph node metastasis. Furthermore, we demonstrate that MAP7D1, regulated by TET1, promotes tumor growth and metastasis. In conclusion, the dynamic 5hmC profiles during lymph node metastasis suggest a link between DNA 5hmC and lymph node metastasis. Meanwhile, the role of MAP7D1 in breast cancer progression suggests that the metastasis-associated 5hmC signatures are potential biomarkers to predict the risk for lymph node metastasis, which may serve as diagnostic and therapeutic targets for metastatic breast cancer.

[1]  Z. Bago-Horvath,et al.  Lymph node blood vessels provide exit routes for metastatic tumor cell dissemination in mice , 2018, Science.

[2]  Yi Zhang,et al.  Tet1 and 5-hydroxymethylation , 2011, Cell cycle.

[3]  G. Pfeifer,et al.  Tet-Mediated Formation of 5-Hydroxymethylcytosine in RNA , 2014, Journal of the American Chemical Society.

[4]  Fang Fang,et al.  Breast Cancer Methylomes Establish an Epigenomic Foundation for Metastasis , 2011, Science Translational Medicine.

[5]  B. Langmead,et al.  Aligning Short Sequencing Reads with Bowtie , 2010, Current protocols in bioinformatics.

[6]  J. Lloreta,et al.  Manual Versus Laser Micro-dissection in Molecular Biology , 2006, Ultrastructural pathology.

[7]  Rong Li,et al.  Whole-genome analysis of 5-hydroxymethylcytosine and 5-methylcytosine at base resolution in the human brain , 2013, Genome Biology.

[8]  Fidel Ramírez,et al.  deepTools: a flexible platform for exploring deep-sequencing data , 2014, Nucleic Acids Res..

[9]  J. Issa,et al.  TET1-Mediated Hypomethylation Activates Oncogenic Signaling in Triple-Negative Breast Cancer. , 2018, Cancer research.

[10]  K. Ori-McKenney,et al.  ReMAPping the microtubule landscape: How phosphorylation dictates the activities of microtubule‐associated proteins , 2018, Developmental dynamics : an official publication of the American Association of Anatomists.

[11]  Doheon Lee,et al.  Dynamic changes in DNA methylation and hydroxymethylation when hES cells undergo differentiation toward a neuronal lineage. , 2014, Human molecular genetics.

[12]  S. PratherRandall,et al.  Methylated DNA Immunoprecipitation and High-Throughput Sequencing (MeDIP-seq) Using Low Amounts of Genomic DNA , 2014 .

[13]  Jun Zhang,et al.  5-Hydroxymethylcytosine signatures in circulating cell-free DNA as diagnostic biomarkers for human cancers , 2017, Cell Research.

[14]  M. Swartz,et al.  Lymphatic and interstitial flow in the tumour microenvironment: linking mechanobiology with immunity , 2012, Nature Reviews Cancer.

[15]  Zechen Chong,et al.  Redox-active quinones induces genome-wide DNA methylation changes by an iron-mediated and Tet-dependent mechanism , 2013, Nucleic acids research.

[16]  H. Hakonarson,et al.  ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.

[17]  Colm E. Nestor,et al.  Tissue type is a major modifier of the 5-hydroxymethylcytosine content of human genes. , 2012, Genome research.

[18]  B. Panning,et al.  OGT binds a conserved C-terminal domain of TET1 to regulate TET1 activity and function in development , 2017, bioRxiv.

[19]  B. Panning,et al.  OGT binds a conserved C-terminal domain of TET1 to regulate TET1 activity and function in development , 2017, bioRxiv.

[20]  Abraham J. Khorasani,et al.  Loss of 5-Hydroxymethylcytosine Is an Epigenetic Hallmark of Melanoma , 2012, Cell.

[21]  P. Jin,et al.  Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine , 2011, Nature Biotechnology.

[22]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[23]  Huanming Yang,et al.  Coexisting genomic aberrations associated with lymph node metastasis in breast cancer , 2018, The Journal of clinical investigation.

[24]  R. Stark,et al.  DiffBind : Differential binding analysis of ChIP-Seq peak data , 2012 .

[25]  S. Mohammed,et al.  Breast cancer metastasis and the lymphatic system (Review) , 2015 .

[26]  Michael Detmar,et al.  Mechanisms of lymphatic metastasis. , 2014, The Journal of clinical investigation.

[27]  Shuhui Song,et al.  RNA m6A methylation participates in regulation of postnatal development of the mouse cerebellum , 2018, Genome Biology.

[28]  Eelco F. J. Meijer,et al.  Lymph node metastases can invade local blood vessels, exit the node, and colonize distant organs in mice , 2018, Science.

[29]  Christopher M. Fife,et al.  Movers and shakers: cell cytoskeleton in cancer metastasis , 2014, British journal of pharmacology.

[30]  Ke Chen,et al.  Loss of 5-hydroxymethylcytosine is linked to gene body hypermethylation in kidney cancer , 2015, Cell Research.

[31]  W. Reik,et al.  Dynamic regulation of 5-hydroxymethylcytosine in mouse ES cells and during differentiation , 2011, Nature.

[32]  L. Cope,et al.  Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer , 2011, Nature Biotechnology.

[34]  George D. Cresswell,et al.  The Spatiotemporal Evolution of Lymph Node Spread in Early Breast Cancer , 2018, Clinical Cancer Research.

[35]  Miao Yu,et al.  Subtelomeric hotspots of aberrant 5-hydroxymethylcytosine-mediated epigenetic modifications during reprogramming to pluripotency , 2013, Nature Cell Biology.

[36]  S. Vowler,et al.  5-hydroxymethylcytosine marks promoters in colon that resist DNA hypermethylation in cancer , 2015, Genome Biology.

[37]  M. Esteller,et al.  DNA methylation profiling in the clinic: applications and challenges , 2012, Nature Reviews Genetics.

[38]  P. Verma,et al.  C-Terminal Region of MAP7 Domain Containing Protein 3 (MAP7D3) Promotes Microtubule Polymerization by Binding at the C-Terminal Tail of Tubulin , 2014, PloS one.

[39]  Meenhard Herlyn,et al.  Axis of evil: molecular mechanisms of cancer metastasis , 2003, Oncogene.

[40]  Cedric E. Ginestet.  ggplot2: Elegant Graphics for Data Analysis , 2011 .

[41]  Qian Zhang,et al.  GSA: Genome Sequence Archive* , 2017, Genom. Proteom. Bioinform..

[42]  Bert A van der Reijden,et al.  5-Hydroxymethylcytosine: An epigenetic mark frequently deregulated in cancer. , 2015, Biochimica et biophysica acta.

[43]  Colm E. Nestor,et al.  5-Hydroxymethylcytosine Profiling in Human DNA. , 2015, Methods in molecular biology.

[44]  Z. Ling,et al.  Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation , 2013, Oncogene.

[45]  T. Uemura,et al.  Map7/7D1 and Dvl form a feedback loop that facilitates microtubule remodeling and Wnt5a signaling , 2018, EMBO reports.

[46]  A. Cochran,et al.  Tumour–induced immune modulation of sentinel lymph nodes , 2006, Nature Reviews Immunology.

[47]  Guangchuang Yu,et al.  clusterProfiler: an R package for comparing biological themes among gene clusters. , 2012, Omics : a journal of integrative biology.

[48]  Sheng F Huang,et al.  Reduction of global 5-hydroxymethylcytosine is a poor prognostic factor in breast cancer patients, especially for an ER/PR-negative subtype , 2015, Breast Cancer Research and Treatment.

[49]  S. Xi,et al.  Decrease in Lymphoid Specific Helicase and 5-hydroxymethylcytosine Is Associated with Metastasis and Genome Instability , 2017, Theranostics.

[50]  Clifford A. Meyer,et al.  Model-based Analysis of ChIP-Seq (MACS) , 2008, Genome Biology.

[51]  Chuan He,et al.  TET1 regulates hypoxia-induced epithelial-mesenchymal transition by acting as a co-activator , 2014, Genome Biology.

[52]  I. Sancho-Martinez,et al.  Hypoxia Drives Breast Tumor Malignancy through a TET-TNFα-p38-MAPK Signaling Axis. , 2015, Cancer research.

[53]  Pedro M. Valero-Mora,et al.  ggplot2: Elegant Graphics for Data Analysis , 2010 .

[54]  Wenying Xiong,et al.  The role of 5-hydroxymethylcytosine in human cancer , 2014, Cell and Tissue Research.

[55]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[56]  Björn Usadel,et al.  Trimmomatic: a flexible trimmer for Illumina sequence data , 2014, Bioinform..

[57]  A. Rao,et al.  Connections between TET proteins and aberrant DNA modification in cancer. , 2014, Trends in genetics : TIG.

[58]  S. Mohammed,et al.  Breast cancer metastasis and the lymphatic system. , 2015, Oncology letters.

[59]  Z. Wang,et al.  MicroRNA-29a induces loss of 5-hydroxymethylcytosine and promotes metastasis of hepatocellular carcinoma through a TET–SOCS1–MMP9 signaling axis , 2017, Cell Death and Disease.